Long-term blood thinner use in a patient with severe hemophilia A
Reports the case of one patient with severe hemophilia A taking long-term anticoagulation.
Plain-language title generated from the registry record
Registry title: Long-term Anticoagulation in a Patient With Severe Hemophilia A
Key facts
- Where
- Strasbourg, FranceSee the site
Where in France
- Laboratoire d'Hématologie - Unité d'Hémostase - CHU de Strasbourg - FranceStrasbourg, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Strasbourg, France
- Trial code
- NCT07314983
- Record updated
- 2 January 2026
- Original description
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of <1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.Read full original descriptionShow less
Report of a Clinical-biological Case: "Long-term Anticoagulation in a Patient With Severe Hemophilia A
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of <1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.
Inclusion: Adult patient (≥ 18 years) with severe hemophilia A; Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.
Exclusion: Subject having expressed objection to the reuse of their data for scientific research.